KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

Daniel P. Petrylak; Raffaele Ratta; Rustem Gafanov; Gaetano Facchini; Josep M. Piulats; Gero Kramer; Thomas W. Flaig; Sreenivasa R. Chandana; Ben Li; Joseph Burgents; Karim Fizazi

doi:10.2217/fon-2020-1133

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

Daniel P. Petrylak, Raffaele Ratta, Rustem Gafanov, Gaetano Facchini, Josep M. Piulats, Gero Kramer, Thomas W. Flaig, Sreenivasa R. Chandana, Ben Li, Joseph Burgents, Karim Fizazi

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only modest survival benefit. Thus, an unmet need remains for mCRPC patients after treatment with targeted endocrine therapy or NHA therapy. Pembrolizumab, a humanized monoclonal antibody for PD-1, has been found to have activity as monotherapy in patients with mCRPC and as combination therapy in a Phase Ib/II study with docetaxel and prednisone/prednisolone for patients previously treated with enzalutamide or abiraterone acetate. The aim of the randomized, double-blind, Phase III KEYNOTE-921 study is to evaluate the efficacy and safety of pembrolizumab plus docetaxel in patients with mCRPC who were previously treated with an NHA.

Original language	English
Pages (from-to)	3291-3299
Number of pages	9
Journal	Future Oncology
Volume	17
Issue number	25
DOIs	https://doi.org/10.2217/fon-2020-1133
Publication status	Published - 1 Sept 2021

Keywords

metastatic castration-resistant prostate cancer
pembrolizumab

Access to Document

10.2217/fon-2020-1133

Cite this

@article{0d973247ffe04046802a13b4b8490cae,

title = "KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer",

abstract = "Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only modest survival benefit. Thus, an unmet need remains for mCRPC patients after treatment with targeted endocrine therapy or NHA therapy. Pembrolizumab, a humanized monoclonal antibody for PD-1, has been found to have activity as monotherapy in patients with mCRPC and as combination therapy in a Phase Ib/II study with docetaxel and prednisone/prednisolone for patients previously treated with enzalutamide or abiraterone acetate. The aim of the randomized, double-blind, Phase III KEYNOTE-921 study is to evaluate the efficacy and safety of pembrolizumab plus docetaxel in patients with mCRPC who were previously treated with an NHA.",

keywords = "metastatic castration-resistant prostate cancer, pembrolizumab",

author = "Petrylak, {Daniel P.} and Raffaele Ratta and Rustem Gafanov and Gaetano Facchini and Piulats, {Josep M.} and Gero Kramer and Flaig, {Thomas W.} and Chandana, {Sreenivasa R.} and Ben Li and Joseph Burgents and Karim Fizazi",

note = "Publisher Copyright: {\textcopyright} 2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.",

year = "2021",

month = sep,

day = "1",

doi = "10.2217/fon-2020-1133",

language = "English",

volume = "17",

pages = "3291--3299",

journal = "Future Oncology",

issn = "1479-6694",

number = "25",

}

TY - JOUR

T1 - KEYNOTE-921

T2 - Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

AU - Petrylak, Daniel P.

AU - Ratta, Raffaele

AU - Gafanov, Rustem

AU - Facchini, Gaetano

AU - Piulats, Josep M.

AU - Kramer, Gero

AU - Flaig, Thomas W.

AU - Chandana, Sreenivasa R.

AU - Li, Ben

AU - Burgents, Joseph

AU - Fizazi, Karim

PY - 2021/9/1

Y1 - 2021/9/1

N2 - Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only modest survival benefit. Thus, an unmet need remains for mCRPC patients after treatment with targeted endocrine therapy or NHA therapy. Pembrolizumab, a humanized monoclonal antibody for PD-1, has been found to have activity as monotherapy in patients with mCRPC and as combination therapy in a Phase Ib/II study with docetaxel and prednisone/prednisolone for patients previously treated with enzalutamide or abiraterone acetate. The aim of the randomized, double-blind, Phase III KEYNOTE-921 study is to evaluate the efficacy and safety of pembrolizumab plus docetaxel in patients with mCRPC who were previously treated with an NHA.

AB - Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only modest survival benefit. Thus, an unmet need remains for mCRPC patients after treatment with targeted endocrine therapy or NHA therapy. Pembrolizumab, a humanized monoclonal antibody for PD-1, has been found to have activity as monotherapy in patients with mCRPC and as combination therapy in a Phase Ib/II study with docetaxel and prednisone/prednisolone for patients previously treated with enzalutamide or abiraterone acetate. The aim of the randomized, double-blind, Phase III KEYNOTE-921 study is to evaluate the efficacy and safety of pembrolizumab plus docetaxel in patients with mCRPC who were previously treated with an NHA.

KW - metastatic castration-resistant prostate cancer

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85113398819&partnerID=8YFLogxK

U2 - 10.2217/fon-2020-1133

DO - 10.2217/fon-2020-1133

M3 - Article

C2 - 34098744

AN - SCOPUS:85113398819

SN - 1479-6694

VL - 17

SP - 3291

EP - 3299

JO - Future Oncology

JF - Future Oncology

IS - 25

ER -

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

Abstract

Keywords

Access to Document

Other files and links

Cite this